<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777073</url>
  </required_header>
  <id_info>
    <org_study_id>1974</org_study_id>
    <nct_id>NCT02777073</nct_id>
  </id_info>
  <brief_title>Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes</brief_title>
  <acronym>1974</acronym>
  <official_title>Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and&#xD;
           urine following a single dose treatment of either liraglutide 1.8mg,dapagliflozin 10mg&#xD;
           or placebo in insulinopenic state.&#xD;
&#xD;
        2. To compare plasma levels of free fatty acid, glucagon, hs-CRP, Il-6 and IL-1 before and&#xD;
           after administration of liraglutide/Dapagliflozin/placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic ketoacidosis is an important cause of mortality and morbidity in type 1 patients.&#xD;
      The decreased ratio of insulin to glucagon in insulin deficient subjects promotes&#xD;
      ketogenesis. In patients with type 1 diabetes, the suppressive effect of hyperglycemia and&#xD;
      the paracrine inhibitory effect of insulin and GABA from the β cell on α cell are absent.&#xD;
      Thus, plasma glucagon concentrations are elevated and in combination with insulin deficiency,&#xD;
      lead to lipolysis, increased plasma FFA concentrations and an increased fatty acid supply to&#xD;
      the liver. Thus, both fatty acid oxidation and ketogenesis are enhanced.&#xD;
&#xD;
      Our recent work has shown that liraglutide, a GLP 1 agonist, improves glycemic control and&#xD;
      reduces glycemic excursions in patients with type 1 diabetes within a few days of the&#xD;
      initiation of treatment.&#xD;
&#xD;
      With this background, the investigators hypothesize that suppression of glucagon with&#xD;
      liraglutide in patients with type 1 diabetes may protect them from lipolysis, increased&#xD;
      bio-availability of FFAs, ketogenesis and ketoacidosis. On the other hand, addition of SGLT 2&#xD;
      inhibitor can shift these biochemical changes to other direction thus increasing ketogenesis&#xD;
      /ketoacidosis.&#xD;
&#xD;
      It is essential to investigate this area further as there are no prior studies that have&#xD;
      investigated the acute effects of liraglutide/Dapagliflozin on FFAs or ketogenesis. This&#xD;
      study will be the first randomized controlled prospective study investigating the effect of&#xD;
      liraglutide/dapagliflozin on ketogenesis. Also, it would be important to measure the&#xD;
      mediators of inflammation at the same time to investigate whether there is a concomitant&#xD;
      changes of inflammatory factors in parallel with the lipolysis and ketogenesis.&#xD;
&#xD;
      After the screening visit, subjects who meet the inclusion and exclusion criteria will be&#xD;
      randomized to receive a single dose of either liraglutide, dapagliflozin or placebo and will&#xD;
      be monitored for a total of 8 hours. The same patient (as described in 8.3, cross over&#xD;
      study), will get the other 2 treatments in random order in the following 2 visits (one week&#xD;
      apart) for a total participation of 2 weeks+1 day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in ketone bodies formation after single dose of liraglutide and dapagliflozin</measure>
    <time_frame>8 hours</time_frame>
    <description>To compare levels of ketone bodies (beta-hydroxybutyrate and acetoacetate) in plasma and urine following a single dose treatment of either liraglutide 1.8mg,dapagliflozin 10mg or placebo in insulinopenic state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on glucagon concentrations</measure>
    <time_frame>8 hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for glucagon over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on Free Fatty Acid</measure>
    <time_frame>8 hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for Free Fatty Acid over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on C-Reactive Protein</measure>
    <time_frame>8 Hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for C-reactive protein over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect of liraglutide and dapagliflozin on IL-6 and IL1-b</measure>
    <time_frame>8 hours</time_frame>
    <description>This secondary endpoint compares the area under the curve for IL-6 and IL1-b over a period of 8 hours following liraglutide and dapagliflozin compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>liraglutide 1.8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of Victoza ( liraglutide) 1.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of Farxiga ( dapagliflozin) 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Farxiga</intervention_name>
    <description>Single dose of dapagliflozin</description>
    <arm_group_label>dapagliflozin 10</arm_group_label>
    <other_name>dapagliflozin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victoza</intervention_name>
    <description>Single dose of Liraglutide</description>
    <arm_group_label>liraglutide 1.8 mg</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of generic placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII, also known as&#xD;
             insulin pump).&#xD;
&#xD;
          2. Undetectable c peptide (c-peptide &lt; 0.1 ng/ml).&#xD;
&#xD;
          3. HbA1c of less than or equal to 8.5%.&#xD;
&#xD;
          4. Age 18-75 inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 diabetes for less than 12 months&#xD;
&#xD;
          2. Coronary event/ procedure (MI, Unstable angina, CABG, PCI) in the last four weeks&#xD;
&#xD;
          3. Hepatic disease (Transaminase &gt; 3 times normal) or Cirrhosis&#xD;
&#xD;
          4. Renal impairment (serum eGFR &lt;30ml/min/1.73m2)&#xD;
&#xD;
          5. HIV or Hepatitis B or C positive status&#xD;
&#xD;
          6. History of pancreatitis, i.e., history of gallstones, alcohol abuse and&#xD;
             hypertriglyceridemia&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Inability to give informed consent&#xD;
&#xD;
          9. History of Gastroparesis&#xD;
&#xD;
         10. Personal or Family History of medullary thyroid carcinoma or MEN 2 syndrome&#xD;
&#xD;
         11. Alcoholism&#xD;
&#xD;
         12. Hypertriglyceridemia (&gt;500 mg/dl).&#xD;
&#xD;
         13. Those with history of bladder cancer , diabetic ketoacidosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ECMC Ambulatory Center, 3rd Floor</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>Distinguished Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetic ketoacidosis</keyword>
  <keyword>Insulin</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>glucose (sugar) control</keyword>
  <keyword>SGLT-2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

